This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Advances & Controversies in Malignant Hematology & Oncology: Hematology Expert Insights

Advances & Controversies in Malignant Hematology & Oncology: Hematology Expert Insights

Format

Roundtable

Time to Complete

30 minutes

Released

December 9, 2016

Expires

December 9, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM
0.05 / Contact Hours for Nurses (0.05 CEU)
0.50 / CE for Pharmacists

Accredited Provider



Provided by the Academy for Continued Healthcare Learning

Sponsor

This activity is sponsored by Cancer Treatment Centers of America (CTCA).

Program Description

Advances & Controversies in Malignant Hematology & Oncology is a one-day comprehensive meeting that presents the latest data and cutting-edge updates in the rapidly evolving fields of malignant hematology and oncology. Advances & Controversies is unique in that it addresses questions and controversies emerging from the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and other major disease-specific conferences. Faculty from Advances & Controversies were interviewed and asked to engage in a commentary style recording so that individuals who could not participate in the live conference can still benefit from these teachings/learnings. This program compiles those interviews in a viewer-friendly webcast presentation with a focus on malignant hematology.

Intended Audience

Healthcare providers involved in the care of oncology patients, including medical and surgical oncologists, hematologists, radiation oncologists and diagnostic radiologists, pathologists, oncology fellows and resident trainees, advanced care practitioners, physician assistants, nurses, naturopathic physicians and pharmacists.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss new data emerging from ASH, ASCO and major disease-specific conferences and implications on the current standards of care*
  • Describe how genetic and cellular abnormalities influence disease severity and therapy selection
  • Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
  • Review how to initiate and individualize therapy
  • Utilize current standards of care for patients with cancer

*This educational program is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.


Pharmacist Educational Objectives

Upon completion of this activity, participants will be able to:

  • Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
  • Review how to initiate and individualize therapy

Agenda

  • Acute Leukemias & Chronic Myelogenous Leukemia
  • Updates in Chronic Lymphocytic Leukemia
  • Hodgkin Lymphoma & Indolent Non-Hodgkin Lymphomas
  • Aggressive Non-Hodgkin Lymphomas
  • Myeloproliferative Neoplasms
  • Multiple Myeloma & the Evolving Role of Transplant

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

Faculty

Syed A. Abutalib, MD (Program Chair)
Assistant Director
Stem Cell Transplant & Cell Therapy Program
Cancer Treatment Centers of America
Zion, IL

Dr. Abutalib has no relevant affiliations or financial relationships to disclose.

Jennifer R. Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Brown discloses the following:
Consultant – Celgene, Gilead, Infinity Pharmaceuticals, Janssen, Pharmacyclics/Janssen, Roche/Genentech

Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Icahn School of Medicine
Director, Myeloproliferative Disorders Research
Program, Tisch Cancer Institute
Mount Sinai Hospital
New York, NY

Dr. Hoffman has no relevant affiliations or financial relationships to disclose.

C. Ola Landgren, MD, PhD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Landgren has no relevant affiliations or financial relationships to disclose.

Jerald P. Radich, MD
Professor of Medicine, University of Washington
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Dr. Radich discloses the following:
Consulting – BMS, Novartis

John W. Sweetenham, MD, FRCP
Professor of Medicine, Department of Hematology
University of Utah
Executive Medical Director and Senior Director of Clinical Affairs
Huntsman Cancer Institute
Salt Lake City, UT

Dr. Sweetenham discloses the following:
Consultant – Sandoz, Seattle Genetics
Honorarium Recipient – Seattle Genetics

Jane N. Winter, MD
Professor of Medicine, Division of Hematology/Oncology
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL

Dr. Winter discloses the following:
Research – Celgene, GSK, Pharmacyclics/Janssen, Medivation, Seattle Genetics
Consultant – Celgene

Accredited Provider Disclosure

ACHL and CTCA staff members and others involved with the planning, development and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.05

Type

CE for Nurses

Accreditation Statement

The Academy for Continued Healthcare Learning has been accredited as an Authorized Provider by the International Association for Continuing Education and training (IACET).

Designation Statement

ACHL is authorized by IACET to offer 0.05 CEU for this program. IACET CEUs are accepted by the American Nursing Association. Contact your licensing agency for details.

0.05 CEU = 30 minutes

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This activity has been approved for 0.5 contact hours.
ACPE Universal Activity Number: 0396-9999-16-054-H01-P
Activity Type: Knowledge
Release Date: 12/9/2016
Expiration Date: 12/9/2017

Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

ACHL requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity. Physicians should consult the current manufacturers’ prescribing information for these products.

Disclaimer

All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

To obtain credit, a score of 60% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Vanessa Senatore
Program Director, ACHL
vsenatore@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity